logo
logo

Topas Therapeutics Appoints Hugo Fry As Chief Executive Officer

May 07, 2024about 1 year ago

Position

Chief Executive Officer

Company

Topas Therapeutics

Hugo Fry
Germany

Description

Topas Therapeutics announced the appointment of Hugo Fry as its new Chief Executive Officer. Hugo brings three decades of experience, with significant track record in leading companies from early research and development through product commercialization.

Company Information

Company

Topas Therapeutics

Location

Germany

About

Topas Therapeutics GmbH is a clinical-stage, private biotechnology company, which focuses on developing nanoparticle-based therapeutics to address areas of major unmet need, including autoimmune diseases, allergies, and anti-drug immune responses. The Topas Particle Conjugates technology platform induces antigen-specific immune tolerance by harnessing the liver's natural tolerization capabilities. The Company has several proprietary programs; lead product candidate, TPM203, is in clinical testing for pemphigus vulgaris, an orphan disease. A second program, TPM 502, is being developed for the treatment of celiac disease and expected to enter the clinic by the end of the year. Topas has several other proprietary programs, including in rheumatoid arthritis and Type I diabetes, in pre-clinical development. Other programs are in the area of anti-drug immune responses, such as in gene therapy and with anti-drug antibodies and are available for partnering. Topas' investors are: BioMedPartners, Boehringer Ingelheim Venture Fund, EMBL Ventures, Epidarex Capital, Evotec, Gimv and Vesalius Biocapital III. For additional information, please visit www.topas-therapeutics.com .

TalentWatch™ Score

83
High Hiring Activity

Executive Opportunity Analysis

Get personalized insights on executive opportunities

Executive Insights

Based on hiring data
New executive impact window
87% of new executives make significant technology decisions within first 100 days
Budget influence
C-level executives control 73% of technology spending decisions
Transformation catalyst
65% of new senior hires launch digital transformation initiatives
Vendor review timeline
New executives typically review existing vendors within 6 months

Related People

Hugo hidden